Eloquent 2 trial The trial,<unk>  Therapy for Relapsed or Refractory Multiple Myeloma, also known as the Eloquent 2 trial, studied the efficacy and safety of<unk> . The objective of the study was to determine if the addition of<unk>  with lenalidomide and dexamethasone would increase progression- free survival in patients with refractory multiple myeloma. This randomized, open-label, phase 3, multicenter trial studied patients 18 years and older with multiple myeloma and measurable disease. With 321 patients designated to the<unk>  group and 325 to the control group, the<unk>  group had a significant relative reduction in the risk of disease progression or death. The median progression-free survival for the<unk>  group was 19.4 months compared with 14.9 months in the control group. Additionally, the response rate for the etoluzumab group was 79%, compared to the control group with 66%. Eloquent 3 trial In the Eloquent 3 trial, also known as<unk>  plus Pomalidomide and Dexamethasone for Multiple Myeloma, 117 patients with refractory or relapsed multiple myeloma, and were refractory to lenalidomide and a protease inhibitor, were randomized to either the<unk>  group or the control group. The<unk>  group, with 60 patients, received<unk>  with pomalidomide and dexamethasone and the control group, with 57 patients, received pomalidomide and dexamethasone alone. Among patients that had failed treatment with lenalidomide and a protease inhibitor, death or risk of progression was significantly lower in the<unk>  study arm. The median progression-free survival in the<unk>  study arm was 10.3 months compared to 4.7 months in the control study group, after a 9.1 month follow up period.
Elotuzumab
Pertuzumab
Idarucizumab
Gatipotuzumab
Theralizumab
Alemtuzumab
Etaracizumab
Risankizumab